MALVERN, Pa., April 29, 2016 /PRNewswire/ -- SCILEX Pharmaceuticals, Inc., a company engaged in the development and commercialization of products focused on the treatment of pain, today announced the addition of Bob Rappaport, M.D., to its Scientific Advisory Board.
Dr. Rappaport has more than 30 years of medical expertise in therapeutic areas such as analgesia, a key focus for SCILEX.
SCILEX Chief Executive Officer Anthony Mack said the addition of Dr. Rappaport would assist in the Company’s development of meaningful therapies to help patients treat pain. “Dr. Rappaport is a recognized expert in neurology, analgesia, and anesthesia, a combination of experience which will be of tremendous benefit to SCILEX and help us develop best-in-class products,” he said. “We also recognize and value Dr. Rappaport’s participation in IMMPACT (Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials) and resulting scholarship that has led to improvement in the design of clinical studies for these pain therapies.”
Dr. Rappaport is currently the President and owner of Analgesic Concepts LLC. Previously, he served in various positions at the FDA before moving on to become the Division Director for Anesthesia, Analgesia, and Addiction Products at the Center for Drug Evaluation and Research for twelve years. He was also Assistant Professor of Neurology at George Washington University, an Administrative Director in the university’s neurology residency program, and Director of the Sleep Disorders Clinic/Laboratory.
Dr. Rappaport has published a range of academic papers, covering topics which include chronic pain treatment and pain measures within clinical studies. He has received several honors in recognition of his contribution to the fields of neurology, biophysics and sleep disorders, including the FDA Lifetime Achievement Award. He is certified with the American Board of Psychiatry and Neurology and earned his M.D. from the George Washington University School of Medicine.
This addition brings SCILEX’s Scientific Advisory Board to six members, with Dr. Rappaport joining Dr. Jeff Gudin, Dr. Howard Maibach, Dr. Charles Argoff, Dr. Sanjay Gupta and Dr. Srinivas Nalamachu.
About SCILEX Pharmaceuticals
SCILEX Pharmaceuticals, Inc., located in Malvern, PA, responsibly develops and brings branded pharmaceutical products to market using groundbreaking technologies that maximize quality of life for all. SCILEX is uncompromising in its focus to become the global pharmaceutical leader in pain management. The Company is committed to social, environmental, economic, and ethical responsibility. Dedicated to using internal partnerships, SCILEX strives to deliver the next generation of trailblazing products that are responsible by design. The Company’s lead product under development, ZTlido (lidocaine patch 1.8%), is a branded lidocaine patch formulation for the potential treatment of relieving the pain of postherpetic neuralgia, also referred to as after-shingles pain. For more information, visit www.scilexpharma.com.
ZTlido and Responsible by Design are trademarks owned by SCILEX Pharmaceuticals, Inc.
© 2016 SCILEX Pharmaceuticals, Inc. All Rights Reserved.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/scilex-pharmaceuticals-announces-addition-of-bob-rappaport-md-to-scientific-advisory-board-300259844.html
SOURCE SCILEX Pharmaceuticals, Inc.
